Corcept Therapeutics Incorporated (CORT NASDAQ) stock market data APIs
$74.1821
-1.76(-2.4%)
as of November 7, 2025
Try our APIs with
free plan!
Corcept Therapeutics Incorporated Financial Data Overview
Price chart is built with
Anychart
Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Prev. Close
74.1821
Open
72.4232
High
74.5491
Low
72.0569
52 wk Range
49-117.33
Market Cap
7 754 M
P/E Ratio
84.7356
Shares Outstanding
105 M
Revenue
741 M
EPS
0.16
Beta
0.2
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Corcept Therapeutics Incorporated (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Corcept Therapeutics Incorporated data using free add-ons & libraries
Get Corcept Therapeutics Incorporated Fundamental Data
Corcept Therapeutics Incorporated Fundamental data includes:
- Net Revenue: 741 M
- EBITDA: 66 713 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-29
- EPS/Forecast: 0.1344
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Corcept Therapeutics Incorporated News
New
Does Recent Pipeline Progress Justify Corcept’s 53% Rally in 2025?
Wondering if Corcept Therapeutics is a bargain or already priced to perfection? Let's dig into what is driving interest in the stock right now. Corcept's shares have had an eye-catching run this year,...
Corcept Q3 Earnings & Revenues Lag Estimates, '25 View Cut, Stock Down
Corcept Therapeutics CORT reported third-quarter 2025 earnings of 16 cents per share, which missed the Zacks Consensus Estimate of 18 cents. The company had reported earnings of 41 cents per share in ...
CORT Q3 Deep Dive: Pharmacy Transition and Pipeline Expansion Drive Mixed Outlook
Biopharma company Corcept Therapeutics (NASDAQ:CORT) missed Wall Street’s revenue expectations in Q3 CY2025, but sales rose 13.7% year on year to $207.6 million. The company’s full-year revenue gu...
Corcept Therapeutics Inc (CORT) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst Net ...
This article first appeared on GuruFocus. Revenue: $207.6 million in Q3 2025, up from $182.5 million in the prior year period. Net Income: $19.7 million, down from $47.2 million in Q3 2024. Cash and ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
